Summary The latest Pharmaceutical and Healthcare disease pipeline guide Postoperative Ileus - Pipeline Review, H2 2019, provides an overview of the Postoperative Ileus (Gastrointestinal) pipeline landscape.
Post-operative ileus describes as an arrest in intestinal motility following surgery. Symptoms include abdominal cramping, appetite loss, feeling of fullness, constipation, inability to pass gas, stomach swelling, nausea and vomiting.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Postoperative Ileus - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Postoperative Ileus (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Postoperative Ileus (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Postoperative Ileus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 1 and 1 respectively.
Postoperative Ileus (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Postoperative Ileus (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Postoperative Ileus (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Postoperative Ileus (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Postoperative Ileus (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Postoperative Ileus (Gastrointestinal)
Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Postoperative Ileus (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Postoperative Ileus (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
Executive Summary Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market was valued at USD 5.5 billion in the year 2020. The key factors driving growth in the global Gastroesophageal Reflux Disease Therapeutics market is increased public awareness of the disease and its symptoms. The growing incidence of heartburn...
Orexin Receptor Type 1 - Drugs In Development, 2021 Summary Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Orexin receptor type 1 (Ox1R or OX1) is a protein that is encoded by the HCRTR1 gene. The orexin 1 receptor (OX1) is a G-protein coupled receptor that is highly expressed in...
Leiomyosarcoma (Oncology) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Leiomyosarcoma - Drugs In Development, 2021, provides an overview of the Leiomyosarcoma (Oncology) pipeline landscape. Leiomyosarcoma is an aggressive soft tissue...
Retinoic Acid Receptor Gamma - Drugs In Development, 2021 Summary Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG bind as heterodimers to the...
Heparanase - Drugs In Development, 2021 Summary Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 18.104.22.168) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report...
Gastric Inhibitory Polypeptide Receptor - Drugs In Development, 2021 Summary Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 26 molecules. Out of which approximately 23 molecules are developed by companies...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the neurodegenerative disorder therapeutics market are Biogen, Pfizer, Novartis, Sanofi, Teva Pharmaceutical, UCB, Hoffmann- La Roche Ltd, ACADIA Pharmaceuticals Inc., Lundeck A/S and Boehringer Ingeiheim International GmbH. The global neurodegenerative disorder therapeutics market is expected to grow from $14.08 billion...
Brain Tumor Therapeutics market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Brain Tumor Therapeutics Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Brain Tumor Therapeutics types, applications. Further,...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.